ThermoGenesis Holdings Overview

  • Year Founded
  • 1986

Year Founded

  • Status
  • Public

  • Employees
  • 25

Employees

  • Stock Symbol
  • THMO

Stock Symbol

  • Investments
  • 3

ThermoGenesis Holdings General Information

Description

ThermoGenesis Holdings Inc develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. The company markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally-closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. It offers the AutoXpress and BioArchive platforms for automated clinical bio-banking, PXP platform for point-of-care cell-based therapies and CAR-TXpress platform for bio-manufacturing for immuno-oncology applications.

Contact Information

Formerly Known As
TotipotentRX Corp., Cesca Therapeutics, Instacool, Therm0genesis Corp
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 2711 Citrus Road
  • Rancho Cordova, CA 95742
  • United States
+1 (916)
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Stock Exchange
PINX
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 2711 Citrus Road
  • Rancho Cordova, CA 95742
  • United States
+1 (916)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ThermoGenesis Holdings Stock Performance

As of 06-Feb-2025, ThermoGenesis Holdings’s current market cap is $4.75K with 15.8M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$4.75K 15.8M 16.2K -$5.14

ThermoGenesis Holdings Financials Summary

As of 31-Mar-2024, ThermoGenesis Holdings has a trailing 12-month revenue of $9.6M.

In Thousands,
USD
TTM 31-Mar-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 5,233 4,879 8,495 13,803
Revenue 9,610 9,445 10,483 9,294
EBITDA (6,943) (7,740) (5,270) (5,144)
Net Income (14,745) (17,975) (11,270) (11,379)
Total Assets 10,087 11,232 19,386 20,652
Total Debt 6,926 10,556 10,365 10,456
Public Fundamental Data provided by Morningstar, Inc. disclaimer

ThermoGenesis Holdings Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore ThermoGenesis Holdings‘s full profile, request access.

Request a free trial

ThermoGenesis Holdings Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
ThermoGenesis Holdings Inc develops, commercializes and markets a range of automated technologies for CAR-T and other ce
Biotechnology
Rancho Cordova, CA
25 As of 2023

Mont-Saint-Guibert, Belgium
 

Madison, WI
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ThermoGenesis Holdings Competitors (30)

One of ThermoGenesis Holdings’s 30 competitors is Celyad Oncology, a Formerly VC-backed company based in Mont-Saint-Guibert, Belgium.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Celyad Oncology Formerly VC-backed Mont-Saint-Guibert, Belgium
Mirus Bio Formerly PE-Backed Madison, WI
ToolGen Corporation Seoul, South Korea
Precigen Formerly VC-backed Germantown, MD
Orgenesis Corporation Germantown, MD
You’re viewing 5 of 30 competitors. Get the full list »

ThermoGenesis Holdings Patents

ThermoGenesis Holdings Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-10823746-B1 Lateral flow immunoassay test reader and method of use Active 22-May-2020
US-20210364536-A1 Lateral flow immunoassay test reader and method of use Inactive 22-May-2020
EP-3913368-A1 Lateral flow immunoassay test reader and method of use Inactive 22-May-2020
EP-3844478-A4 Methods for isolating target cells from blood Pending 31-Aug-2018
EP-3844478-A1 Methods for isolating target cells from blood Pending 31-Aug-2018 G01N33/56972
To view ThermoGenesis Holdings’s complete patent history, request access »

ThermoGenesis Holdings Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ThermoGenesis Holdings Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore ThermoGenesis Holdings‘s full profile, request access.

Request a free trial

ThermoGenesis Holdings Investments & Acquisitions (3)

ThermoGenesis Holdings’s most recent deal was a Joint Venture with ImmuneCyte Life Sciences. The deal was made on 26-Nov-2019.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
ImmuneCyte Life Sciences 26-Nov-2019 Joint Venture Other Pharmaceuticals and Biotechnology
SynGen 07-Jul-2017 Merger/Acquisition Other Devices and Supplies
ThermoGenesis (Acquired 2014) 19-Feb-2014 Merger/Acquisition Therapeutic Devices
To view ThermoGenesis Holdings’s complete investments and acquisitions history, request access »

ThermoGenesis Holdings FAQs

  • When was ThermoGenesis Holdings founded?

    ThermoGenesis Holdings was founded in 1986.

  • Where is ThermoGenesis Holdings headquartered?

    ThermoGenesis Holdings is headquartered in Rancho Cordova, CA.

  • What is the size of ThermoGenesis Holdings?

    ThermoGenesis Holdings has 25 total employees.

  • What industry is ThermoGenesis Holdings in?

    ThermoGenesis Holdings’s primary industry is Biotechnology.

  • Is ThermoGenesis Holdings a private or public company?

    ThermoGenesis Holdings is a Public company.

  • What is ThermoGenesis Holdings’s stock symbol?

    The ticker symbol for ThermoGenesis Holdings is THMO.

  • What is the current market cap of ThermoGenesis Holdings?

    The current market capitalization of ThermoGenesis Holdings is $4.75K.

  • What is ThermoGenesis Holdings’s current revenue?

    The trailing twelve month revenue for ThermoGenesis Holdings is $9.6M.

  • Who are ThermoGenesis Holdings’s competitors?

    Celyad Oncology, Mirus Bio, ToolGen, Precigen, and Orgenesis are some of the 30 competitors of ThermoGenesis Holdings.

  • What is ThermoGenesis Holdings’s annual earnings per share (EPS)?

    ThermoGenesis Holdings’s EPS for 12 months was -$5.14.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »